Management of Wilms' tumour: Current practice and future goals

John A. Kalapurakal, Jeffrey S. Dome, Elizabeth J. Perlman, Marcio Malogolowkin, Gerald M. Haase, Paul Grundy, Max J. Coppes

Research output: Contribution to journalReview article

136 Scopus citations

Abstract

Most patients with Wilms' tumour in Europe and North America can be cured with treatment and subsequently lead a normal adulthood. However, for some, therapy as applied today results in long-term side-effects and creates a substantial burden on quality of life. Therefore, investigators involved in the management of patients with Wilms' tumour are increasingly focusing their efforts on curtailing the longterm sequelae of therapy. This aim has been achieved by lowering the total amount of chemotherapy, radiotherapy, or both administered to patients who have characteristics associated with favourable outcome. Although excellent survival has been maintained, many patients receive less therapy today than patients with similar characteristics did a decade or two ago. Better understanding of the biological processes that lead to this childhood cancer will allow further improvements in its management.

Original languageEnglish (US)
Pages (from-to)37-46
Number of pages10
JournalLancet Oncology
Volume5
Issue number1
DOIs
StatePublished - Jan 1 2004
Externally publishedYes

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Management of Wilms' tumour: Current practice and future goals'. Together they form a unique fingerprint.

  • Cite this

    Kalapurakal, J. A., Dome, J. S., Perlman, E. J., Malogolowkin, M., Haase, G. M., Grundy, P., & Coppes, M. J. (2004). Management of Wilms' tumour: Current practice and future goals. Lancet Oncology, 5(1), 37-46. https://doi.org/10.1016/S1470-2045(03)01322-6